Neil M Walker

List of Publications by Year in Descending Order

16 papers	987 citations	11 h-index	18 g-index
18 ext. papers	1,220 ext. citations	11.1 avg, IF	2.86 L-index

#	Paper	IF	Citations
16	Coagulation Factor V is a T cell inhibitor expressed by leukocytes in COVID-19.. *IScience*, **2022**, 103971	6.1	1
15	The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes. *JCI Insight*, **2018**, 3,	9.9	11
14	Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2. *JCI Insight*, **2017**, 2,	9.9	26
13	Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial. *Wellcome Open Research*, **2017**, 2, 28	4.8	13
12	Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial. *PLoS Medicine*, **2016**, 13, e1002139	11.6	76
11	Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D). *Trials*, **2015**, 16, 86	2.8	9
10	Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study. *BMJ Open*, **2015**, 5, e009799	3	16
9	Dissection of a Complex Disease Susceptibility Region Using a Bayesian Stochastic Search Approach to Fine Mapping. *PLoS Genetics*, **2015**, 11, e1005272	6	42
8	Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. *Nature Genetics*, **2015**, 47, 381-6	36.3	414
7	Detection and correction of artefacts in estimation of rare copy number variants and analysis of rare deletions in type 1 diabetes. *Human Molecular Genetics*, **2015**, 24, 1774-90	5.6	11
6	Statistical colocalization of genetic risk variants for related autoimmune diseases in the context of common controls. *Nature Genetics*, **2015**, 47, 839-46	36.3	97
5	Returning findings within longitudinal cohort studies: the 1958 birth cohort as an exemplar. *Emerging Themes in Epidemiology*, **2014**, 11, 10	3.9	3
4	A genome-wide assessment of the role of untagged copy number variants in type 1 diabetes. *PLoS Genetics*, **2014**, 10, e1004367	6	16
3	Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial. *BMJ Open*, **2014**, 4, e005559	3	26
2	Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. *Nature Genetics*, **2009**, 41, 1011-5	36.3	224
1	A rare IL2RA haplotype identifies SNP rs61839660 as causal for autoimmunity		2